Holen Sie sich die Stockscreener-App
56.94
2.57%
1.4062
Schlusskurs vom Vortag:
$55.53
Offen:
$56.16
24-Stunden-Volumen:
1.73M
Relative Volume:
0.65
Marktkapitalisierung:
$14.33B
Einnahmen:
$2.38B
Nettoeinkommen (Verlust:
$833.42M
KGV:
18.87
EPS:
3.0172
Netto-Cashflow:
$917.69M
1W Leistung:
+4.68%
1M Leistung:
+8.08%
6M Leistung:
+23.31%
1J Leistung:
+28.98%
1-Tages-Spanne:
$55.80
$57.57
1-Wochen-Bereich:
$53.25
$57.57
52-Wochen-Spanne:
$33.76
$57.57
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
57.00 | 13.96B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
522.41 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.94 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.98 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.29 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.97 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-11-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Eingeleitet | Goldman | Buy |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Exelixis Inc stock hits all-time high at 56.22 USD By Investing.com - Investing.com Canada
RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating - marketscreener.com
(EXEL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with Strong Revenue Growth and High Analyst Interest - DirectorsTalk Interviews
Zanzalintinib Trial Outcomes And Index Exit Might Change The Case For Investing In Exelixis (EXEL) - simplywall.st
ETFs Investing in Exelixis, Inc. Stocks - TradingView
Price to sales forward of Exelixis, Inc. – NASDAQ:EXEL - TradingView
Exelixis, Inc. (EXEL) Stock Price Today - CoinMarketCap
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Santhera Pharmaceuticals Holding (OtherSPHDF) - The Globe and Mail
Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says - Moomoo
UBS raises Exelixis stock price target to $52 on pipeline outlook - Investing.com
EXEL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $56 - GuruFocus
H.C. Wainwright reiterates Exelixis stock rating at Buy, $56 target By Investing.com - Investing.com South Africa
Analyst recommendations: Adobe, AA, Nike, Exelixis… - marketscreener.com
What Does Truist’s New Analyst Think About Exelixis (EXEL) and Its Next-Generation Cancer Drug? - Yahoo Finance
Exelixis | 4: Statement of changes in beneficial ownership of securities-Officer Aftab Dana - Moomoo
Exelixis Inc. (NASDAQ:EXEL): A Decent Value Play in the Biotechnology Sector - ChartMill
Seven Fleet Capital Management LP's Exelixis Inc(EXEL) Holding History - GuruFocus
Exelixis, Inc.(NasdaqGS: EXEL) dropped from Russell 1000 Value-Defensive Index - marketscreener.com
Exelixis, Inc.(NasdaqGS: EXEL) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com
Exelixis, Inc.(NasdaqGS: EXEL) dropped from Russell 1000 Defensive Index - marketscreener.com
Exelixis, Inc. (EXEL) Stock Analysis: Biotechnology Leader with Robust Revenue Growth and High ROE - DirectorsTalk Interviews
Enterprise value to EBITDA forward of Exelixis, Inc. – NASDAQ:EXEL - TradingView
Price to sales forward of Exelixis, Inc. – GETTEX:EX9 - TradingView
Enterprise value to EBITDA forward of Exelixis, Inc. – GETTEX:EX9 - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Exelixis falls as final analysis of zanzalintinib Phase 3 data disappoints - MSN
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib - MSN
Exelixis stock reaches all-time high of 53.97 USD By Investing.com - Investing.com South Africa
Exelixis stock reaches all-time high of 53.97 USD - Investing.com
Exelixis, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh Actuals & Estimates (BMFBOVESPA:E2XE34) - TradingView
Enterprise value to revenue forward of Exelixis, Inc. – NASDAQ:EXEL - TradingView
Exelixis Inc (EXEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Liquidity Mapping Around (EXEL) Price Events - Stock Traders Daily
Price to sales forward of Exelixis, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh – BMFBOVESPA:E2XE34 - TradingView
Exelixis, Inc. Actuals & Estimates (NASDAQ:EXEL) - TradingView
EXEL Downgraded by Truist Securities -- Price Target Raised to $54 - GuruFocus
EXEL Forecast — Price Target — Prediction for 2027 - TradingView
Exelixis, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh - TradingView
This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday - Benzinga
EX9 Forecast — Price Target — Prediction for 2027 - TradingView
Truist assumes Exelixis stock coverage with Hold rating on pipeline uncertainty - Investing.com South Africa
Truist Financial Downgrades Exelixis(EXEL.US) to Hold Rating, Raises Target Price to $54 - Moomoo
Exelixis, Inc. (EXEL) latest stock news and headlines - Yahoo Finance UK
EXELIXIS INC : TRUIST SECURITIES CUTS TO HOLD FROM BUY; RAISES TARGET PRICE TO $54 FROM $51 - Moomoo
Price to earnings forward of Exelixis, Inc. – NASDAQ:EXEL - TradingView
EXEL Maintained by Citizens -- Price Target Raised to $55.00 - GuruFocus
Citizens Jmp Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock - MarketBeat
Exelixis, Inc. (EXEL) Latest Stock News & Headlines - Yahoo! Finance Canada
BofA Securities Maintains Exelixis(EXEL.US) With Sell Rating, Maintains Target Price $41 - Moomoo
Morgan Stanley reiterates Exelixis stock rating on mixed trial data By Investing.com - Investing.com India
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Exelixis Inc-Aktie (EXEL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Eckhardt Sue Gail | Director |
Jun 01 '26 |
Sale |
50.14 |
9,812 |
491,974 |
16,079 |
1.21%
3.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):